title: Disease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ICA, GAD- and IA-2 Antibodies.
abstract: BACKGROUND
  To investigate disease progression the first 12 months after diagnosis in children with type 1 diabetes negative (AAB negative) for pancreatic autoantibodies [islet cell autoantibodies(ICA), glutamic acid decarboxylase antibodies (GADA) and insulinoma-associated antigen-2 antibodies (IA-2A)]. Furthermore the study aimed at determining whether mutations in KCNJ11, ABCC8, HNF1A, HNF4A or INS are common in AAB negative diabetes.
  
  
  METHODS
  In 261 newly diagnosed children with type 1 diabetes, we measured residual β-cell function, ICA, GADA, and IA-2A at 1, 6 and 12 months after diagnosis. The genes KCNJ11, ABCC8, HNF1A, HNF4A and INS were sequenced in subjects AAB negative at diagnosis. We expressed recombinant K-ATP channels in Xenopus oocytes to analyse the functional effects of an ABCC8 mutation.
  
  
  RESULTS
  Twenty-four patients (9.1%) tested AAB negative after one month. Patients, who were AAB-negative throughout the 12-month period, had higher residual β-cell function (P = 0.002), lower blood glucose (P = 0.004), received less insulin (P = 0.05) and had lower HbA1c (P = 0.02) 12 months after diagnosis. One patient had a heterozygous mutation leading to the substitution of arginine at residue 1530 of SUR1 (ABCC8) by cysteine. Functional analyses of recombinant K-ATP channels showed that R1530C markedly reduced the sensitivity of the K-ATP channel to inhibition by MgATP. Morover, the channel was highly sensitive to sulphonylureas. However, there was no effect of sulfonylurea treatment after four weeks on 1.0-1.2 mg/kg/24 h glibenclamide.
  
  
  CONCLUSIONS
  GAD, IA-2A, and ICA negative children with new onset type 1 diabetes have slower disease progression as assessed by residual beta-cell function and improved glycemic control 12 months after diagnosis. One out of 24 had a mutation in ABCC8, suggesting that screening of ABCC8 should be considered in patients with AAB negative type 1 diabetes.
authors.affiliation: Department of Pediatrics, Glostrup Hospital & University of Copenhagen, Copenhagen, Denmark. spoerksen@yahoo.com.
authors.forename: Sven
authors.initials: S
authors.lastname: Pörksen
authors.forename: Lene Bjerke
authors.initials: LB
authors.lastname: Laborie
authors.forename: Lotte
authors.initials: L
authors.lastname: Nielsen
authors.forename: Marie
authors.initials: M
authors.lastname: Louise Max Andersen
authors.forename: Tone
authors.initials: T
authors.lastname: Sandal
authors.forename: Heidi
authors.initials: H
authors.lastname: de Wet
authors.forename: Erik
authors.initials: E
authors.lastname: Schwarcz
authors.forename: Jan
authors.initials: J
authors.lastname: Aman
authors.forename: Peter
authors.initials: P
authors.lastname: Swift
authors.forename: Mirjana
authors.initials: M
authors.lastname: Kocova
authors.forename: Eugen J
authors.initials: EJ
authors.lastname: Schönle
authors.forename: Carine
authors.initials: C
authors.lastname: de Beaufort
authors.forename: Philip
authors.initials: P
authors.lastname: Hougaard
authors.forename: Frances
authors.initials: F
authors.lastname: Ashcroft
authors.forename: Anders
authors.initials: A
authors.lastname: Molven
authors.forename: Mikael
authors.initials: M
authors.lastname: Knip
authors.forename: Henrik B
authors.initials: HB
authors.lastname: Mortensen
authors.forename: Lars
authors.initials: L
authors.lastname: Hansen
authors.forename: Pål R
authors.initials: PR
authors.lastname: Njølstad